• Explore /
  • Poster
  • / Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.

Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.

Abstract Poster

Authors

null

Jeremy S. Abramson

Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, MA

Jeremy S. Abramson , Maria Lia Palomba , Jon E. Arnason , Matthew Alexander Lunning , Scott R. Solomon , Thalia Farazi , Jacob Garcia , Benhuai Xie , Kathryn J. Newhall , Christine Dehner , Tanya Siddiqi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02631044

Citation

J Clin Oncol 37, 2019 (suppl; abstr 7515)

DOI

10.1200/JCO.2019.37.15_suppl.7515

Abstract #

7515

Poster Bd #

269

Abstract Disclosures

Similar Posters

First Author: Alison R. Sehgal

First Author: Jeremy S. Abramson

First Author: Yang Xie

First Author: Donald Patrick